Akademska digitalna zbirka SLovenije - logo
E-resources
Full text
Peer reviewed
  • Geriatric nutritional risk ...
    Kaito, Satoshi; Wada, Atsushi; Adachi, Hiroto; Konuma, Ryosuke; Kishida, Yuya; Nagata, Akihito; Konishi, Tatsuya; Yamada, Yuta; Kumagai, Takuma; Yoshifuji, Kota; Mukae, Junichi; Akiyama, Megumi; Inamoto, Kyoko; Toya, Takashi; Igarashi, Aiko; Najima, Yuho; Muto, Hideharu; Kobayashi, Takeshi; Kakihana, Kazuhiko; Ohashi, Kazuteru; Sakamaki, Hisashi; Doki, Noriko

    Annals of hematology, 07/2020, Volume: 99, Issue: 7
    Journal Article

    Second allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a low survival outcome and a high non-relapse mortality (NRM) rate which is a major obstacle to this treatment. We hypothesized that the status of malnourishment after first allo-HSCT as represented by the geriatric nutritional risk index (GNRI) could be used as a prognostic factor to determine the outcomes of second allo-HSCT. A total of 108 patients with a median age of 42 (range, 17–69) years, who received second allo-HSCT for disease recurrence after first allo-HSCT from our institution, were included in this study. Low GNRI had a significant impact on NRM at 2 years after second allo-HSCT: 56.9% in patients with GNRI ≤ 92 compared with 27.5% in patients with GNRI > 92 ( P  = 0.002). In multivariate analysis, GNRI of ≤ 92 was the only significant factor for NRM (hazard ratio HR 2.29, 95% confidence interval CI 1.15–4.56, P  = 0.018). High-risk disease status at second allo-HSCT (HR 2.74, 95% CI 1.46–5.14, P  = 0.002) and GNRI of ≤ 92 (HR 1.70, 95% CI 1.02–2.82, P  = 0.042) were identified as significant factors for overall survival (OS). A score of 1 was assigned to each factor, and the OS rate at 2 years after second allo-HSCT decreased according to the score: 53.0% in patients with score 0, 32.3% with score 1, and 2.5% with score 2 ( P  < 0.001). In conclusion, GNRI could be a useful predictor for the outcomes of second allo-HSCT. A prospective study in other cohorts is warranted to validate the findings of our study.